Cytokine conjugates for the treatment of autoimmune diseases
US11622993B2 · kind B2 · utility
5Cited by
230References
19Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Aug 3, 2018 |
| Grant date | Apr 11, 2023 |
| Priority date | — |
| Expiry date | Aug 3, 2038 |
Classification
- Technology area (CPC Y)Emerging Cross-Sectional Technologies
- CPC primaryY02A50/30
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Disclosed herein are interleukin (IL) conjugates (e.g., IL-2 conjugates) and use in the treatment of one or more indications. Also described herein are pharmaceutical compositions and kits comprising one or more of the interleukin conjugates (e.g., IL-2 conjugates).
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.